CPE points : 3 per symposium

For more information :

/ufiles/userfiles/files/HKSDO_Inaugural%20Scientific%20Symposium%20poster_20250723.pdf

Learning Objectives of the Symposium

By the end of this symposium, participants will be able to:

1. Apply Personalized Treatment Strategies in mCRC: Evaluate and implement tailored therapeutic approaches for metastatic colorectal cancer (mCRC) by transitioning from population-based to personalized treatment methods, as discussed in Prof. Kei Muro’s lecture on "Tailoring Treatment in mCRC: From Population-Based to Personalized Approaches."
2. Assess the Impact of Dual Immunotherapy in MSI-H/dMMR mCRC: Analyze the transformative role of dual immunotherapy (IO) in improving outcomes for patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) mCRC, based on insights from Prof. Heinz-Josef Lenz’s lecture on "Harnessing Dual IO: Transforming Outcomes for MSI-H/dMMR mCRC Patients."
3. Integrate Advances in HER2-Negative Metastatic Gastric Cancer: Incorporate cutting-edge translational research and clinical advancements in the management of HER2-negative metastatic gastric cancer, as presented in Prof. Dr. Eric Van Cutsem’s lecture on "From Bench to Bedside: Transformative Advances in HER2-Negative Metastatic Gastric Cancer."
4. Evaluate Breakthroughs in Resectable Gastric and Gastroesophageal Junction Cancer: Assess emerging scientific advances and their clinical implications for the treatment of resectable gastric and gastroesophageal junction cancer, as highlighted in Dr. Shannon Melissa Chan’s lecture on "UNLOCKING TOMORROW: Breakthrough Scientific Advances in Resectable Gastric and Gastroesophageal Junction Cancer."
5. Synthesize Multidisciplinary Insights: Integrate knowledge from the colorectal and gastric cancer sessions to enhance clinical decision-making, optimize patient outcomes, and apply innovative, evidence-based therapeutic strategies across diverse cancer types.